These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1706154)

  • 1. Fibrinogen-immobilized urokinase demonstrates increased thrombolytic activity in animal experiments.
    Maksimenko AV; Samarenko MB; Petrov AD; Tischenko EG; Ruda MYa ; Torchilin VP
    Ann N Y Acad Sci; 1990; 613():479-82. PubMed ID: 1706154
    [No Abstract]   [Full Text] [Related]  

  • 2. Immobilized enzymes for thrombolytic therapy.
    Torchilin VP; Maksimenko AV; Mazaev AV
    Methods Enzymol; 1988; 137():552-66. PubMed ID: 2967420
    [No Abstract]   [Full Text] [Related]  

  • 3. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immobilized thrombolytic enzymes for systemic and local application.
    Torchilin VP; Maksimenko AV; Mazaev AV
    Ann N Y Acad Sci; 1987; 501():481-6. PubMed ID: 2955733
    [No Abstract]   [Full Text] [Related]  

  • 5. Fibrin-specific fibrinolysis.
    Collen D; Lijnen HR
    Ann N Y Acad Sci; 1992 Dec; 667():259-71. PubMed ID: 1285022
    [No Abstract]   [Full Text] [Related]  

  • 6. A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity.
    Hirata Y; Umemura K; Takiguchi Y; Uematsu T; Nakashima M
    Blood Coagul Fibrinolysis; 1993 Aug; 4(4):569-75. PubMed ID: 7692999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha 2-macroglobulin in the regulation of pericellular plasminogen activation of human tumor cells.
    Vaheri A; Tapiovaara H; Myöhänen H; Bizik J
    Ann N Y Acad Sci; 1994 Sep; 737():409-18. PubMed ID: 7524411
    [No Abstract]   [Full Text] [Related]  

  • 8. The biological activity of antithrombotic agents immobilized on polymer surfaces.
    Kim SW; Ebert CD; McRea JC; Briggs C; Byun SM; Kim HP
    Ann N Y Acad Sci; 1983; 416():513-24. PubMed ID: 6233925
    [No Abstract]   [Full Text] [Related]  

  • 9. [Thrombolytic treatment: problems and prospects].
    Latallo ZS
    Pol Arch Med Wewn; 1978 Jul; 60(1):1-8. PubMed ID: 151855
    [No Abstract]   [Full Text] [Related]  

  • 10. [Fibrinolytic treatment today].
    Bartolo M; Antignani PL; Ceccarelli V; Murgiano GA; Todini AR
    Clin Ter; 1985 Sep; 114(5):371-9. PubMed ID: 2932278
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of bioresolving microspheric preparations of immobilized fibrinolysin on the fibrinolysis system].
    Bessolitsyna LA; Mazaev AB; Markosian RA; Suvorov AV; Torchilin VP
    Biull Eksp Biol Med; 1980; 89(1):16-8. PubMed ID: 6445763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immobilization of urokinase on agarose matrices.
    Kim HP; Byun SM; Yeom YI; Kim SW
    J Pharm Sci; 1983 Mar; 72(3):225-8. PubMed ID: 6221088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of immobilized enzymes for biomaterials used in surgery.
    Watanabe S; Shimizu Y; Teramatsu T; Murachi T; Hino T
    Methods Enzymol; 1988; 137():545-51. PubMed ID: 3374358
    [No Abstract]   [Full Text] [Related]  

  • 14. alpha 2-Antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy.
    Collen D; Verstraete M
    Thromb Res; 1979; 14(4-5):631-9. PubMed ID: 90396
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Lubbers NL; Nelson RA; Henkin J
    Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.
    Korninger C; Matsuo O; Suy R; Stassen JM; Collen D
    J Clin Invest; 1982 Mar; 69(3):573-80. PubMed ID: 7199539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmin inhibitors in different fibrinolytic treatment patterns.
    Lasierra J; Diez M; Perera C; Viladés E
    Haemostasis; 1981; 10(1):51-62. PubMed ID: 6162721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Compared activation of kinin system by streptokinase and urokinase "in vitro" and during thrombolytic treatments (author's transl)].
    Migne J; Vedrine Y; Conard J; Samama M
    Pathol Biol (Paris); 1977 Dec; 25 Suppl():42-7. PubMed ID: 149942
    [No Abstract]   [Full Text] [Related]  

  • 19. [Urokinase. Biochemical therapeutical and therapeutical data (author's transl)].
    Kher A
    Pathol Biol (Paris); 1976 Dec; 24 Suppl():54-69. PubMed ID: 64958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A spectrophotometric assay for the determination of the catalytic efficiency of plasminogen activators using a slowly hydrolyzed plasmin substrate.
    Castro MJ; Kingston IB; Anderson S
    Anal Biochem; 1995 Apr; 226(2):225-31. PubMed ID: 7793622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.